

CORRECTION

Open Access



Correction: A critical reappraisal of vasopressin and steroids in in-hospital cardiac arrest

Spyros D. Mentzelopoulos^{1,2*} and Athanasios Chalkias^{3,4}

Correction: Mentzelopoulos and Chalkias *Critical Care* (2024) 28:191

<https://doi.org/10.1186/s13054-024-04962-8>

Following publication of the original article [1], the authors identified an error within row 7 of Table 2. In Table 2, row 7, the lowest percentages of postresuscitation hypotension (i.e. 17% and 15%) actually correspond to the intervention group(s) and the highest (i.e. 28% and 29%) to control.

Table 2 row 7 currently reads:

Lowest MAP \leq 50 mmHg and SAP \leq 80 mmHg, intervention group(s) versus control (%)	28% versus 17%— $P=0.12$ and 29% versus 15%; $P=0.03^d$	NR but significant difference unlikely ^c
--------------------------------------------------------------------------------------------	---------------------------------------------------------	-----------------------------------------------------

The original article can be found online at <https://doi.org/10.1186/s13054-024-04962-8>.

*Correspondence:

Spyros D. Mentzelopoulos

sdmentzelopoulos@yahoo.com; sdmentzelopoulos@gmail.com

¹ First Department of Intensive Care Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

² Department of Intensive Care Medicine, Evangelismos General Hospital, 45-47 Ipsilandou St, 10675 Athens, Greece

³ Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104-5158, USA

⁴ Outcomes Research Consortium, Cleveland, OH 44195, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 2 Key differences between the Greek VSE trials and the Danish VAM IHCA trial

Key characteristic	VSE 1 and 2—pooled data	VAM-IHCA (Danish trial)	Potential effect
Time to study drugs, median (IQR)—min	4 (3–5)	9 (6–12)	Earlier, simultaneous activation of V1A-vasopressin and $\alpha 1$ -adrenergic receptors, with maximization of pressor effect and associated probability of prompt ROSC, ^a likely occurring only in intervention groups (vs. control) of the VSE 1 and 2 RCTs
Epinephrine and Vasopressin started and always given simultaneously	Yes	No	
Median time lag between first dose of epinephrine and study drugs (min)	0	3–4	
Significantly shorter median (IQR) time to ROSC (min) in intervention group(s) versus control	Yes; 14 (7–24) versus 20 (10–30)— $P < 0.001$	No; 16 (12–25) versus 18 (11–31)— P -value NR	Attenuated ischemia / reperfusion injury and lower risk of epinephrine-related adverse effects likely present only in intervention groups (vs. control) of the VSE 1 and 2 RCTs
Significantly lower median (IQR) total dose (mg) of epinephrine in intervention group(s) versus control	Yes; 4 (2–6) versus 5 (3–9)— $P < 0.001$	No; 3 (2–5) versus 3 (2–5)— P -value NR	
SAP < 90 mmHg within 20 min of ROSC, intervention group(s) versus control (%)	19% versus 44%— $P < 0.001$ ^b	NR but significant difference unlikely ^c	Early postresuscitation hypotension has been consistently associated with increased in-hospital mortality [1]; reported differences may partly explain the long-term benefit observed only in the VSE 1 and 2 RCTs
Lowest MAP \leq 50 mmHg and SAP \leq 80 mmHg, intervention group(s) versus control (%)	28% versus 17%— $P = 0.12$ and 29% versus 15%, $P = 0.03$ ^d	NR but significant difference unlikely ^c	
Postresuscitation use of steroids in intervention group(s) versus control (%)	99% versus 22% ^d	26% versus 46% ^e	In VAM-IHCA, there was non-protocolized, more frequent use of potentially beneficial interventions in the control group
Postresuscitation use of ECMO in intervention group(s) versus control (%)	0% versus 0% ^{df}	14% versus 30% ^e	

VSE, vasopressin-steroids-epinephrine; VAM, vasopressin-adrenaline-methylprednisolone; IHCA, in-hospital cardiac arrest; IQR, interquartile range; ROSC, return of spontaneous circulation; NR, not reported; RCT, randomized clinical trial; SAP, systolic arterial pressure; MAP, mean arterial pressure; ECMO, extracorporeal membrane oxygenation

Reported data originate from the total of the VSE 1 and 2 or VAM-IHCA participants, unless otherwise specified. For data reported as median (IQR), P -values were determined using the Mann Whitney U test. For data reported as percentages, P -values were determined by Fisher's exact test

^a, Defined as ROSC after ≤ 3 vasopressor doses

^b, VSE 1 and 2 data originate from the pooled subgroup of survivors for ≥ 4 h with postresuscitation shock and available SAP data (intervention, $n = 94$; control, $n = 72$)

^c, Analyses of VAM-IHCA hemodynamic data revealed very similar, early postresuscitation arterial pressures and vasopressor support [2]; consequently, there was likely no significant, between-group difference in the frequency of postresuscitation hypotension

^d, VSE 1 and 2 data originate from the pooled subgroup of survivors for ≥ 24 h (intervention, $n = 94$; control, $n = 69$)

^e, VAM-IHCA data originate from survivors for ≥ 24 h (intervention, $n = 63$; control, $n = 61$)

^f, There was no postresuscitation use of ECMO in the VSE 1 and 2 studies

Table 2 row 7 should read:

Lowest MAP \leq 50 mmHg and SAP \leq 80 mmHg, intervention group(s) versus control (%)	17% versus 28%— $P=0.12$ and 15% ver- sus 29%; $P=0.03^d$	NR but significant differ- ence unlikely ^c
--------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------	----------------------------------------------------------

Table 2 Key differences between the Greek VSE trials and the Danish VAM IHCA trial

Key characteristic	VSE 1 and 2—pooled data	VAM-IHCA (Danish trial)	Potential effect
Time to study drugs, median (IQR)—min	4 (3–5)	9 (6–12)	Earlier, simultaneous activation of V1A-vasopressin and $\alpha 1$ -adrenergic receptors, with maximization of pressor effect and associated probability of prompt ROSC, ^a likely occurring only in intervention groups (vs. control) of the VSE 1 and 2 RCTs
Epinephrine and Vasopressin started and always given simultaneously	Yes	No	
Median time lag between first dose of epinephrine and study drugs (min)	0	3–4	
Significantly shorter median (IQR) time to ROSC (min) in intervention group(s) versus control	Yes; 14 (7–24) versus 20 (10–30)— $P < 0.001$	No; 16 (12–25) versus 18 (11–31)— P -value NR	Attenuated ischemia / reperfusion injury and lower risk of epinephrine-related adverse effects likely present only in intervention groups (vs. control) of the VSE 1 and 2 RCTs
Significantly lower median (IQR) total dose (mg) of epinephrine in intervention group(s) versus control	Yes; 4 (2–6) versus 5 (3–9)— $P < 0.001$	No; 3 (2–5) versus 3 (2–5)— P -value NR	
SAP < 90 mmHg within 20 min of ROSC, intervention group(s) versus control (%)	19% versus 44%— $P < 0.001$ ^b	NR but significant difference unlikely ^c	Early postresuscitation hypotension has been consistently associated with increased in-hospital mortality [1]; reported differences may partly explain the long-term benefit observed only in the VSE 1 and 2 RCTs
Lowest MAP \leq 50 mmHg and SAP \leq 80 mmHg, intervention group(s) versus control (%)	17% versus 28%— $P = 0.12$ and 15% versus 29%, $P = 0.03$ ^d	NR but significant difference unlikely ^c	
Postresuscitation use of steroids in intervention group(s) versus control (%)	99% versus 22% ^d	26% versus 46% ^e	In VAM-IHCA, there was non-protocolized, more frequent use of potentially beneficial interventions in the control group
Postresuscitation use of ECMO in intervention group(s) versus control (%)	0% versus 0% ^{df}	14% versus 30% ^e	

VSE, vasopressin-steroids-epinephrine; VAM, vasopressin-adrenaline-methylprednisolone; IHCA, in-hospital cardiac arrest; IQR, interquartile range; ROSC, return of spontaneous circulation; NR, not reported; RCT, randomized clinical trial; SAP, systolic arterial pressure; MAP, mean arterial pressure; ECMO, extracorporeal membrane oxygenation

Reported data originate from the total of the VSE 1 and 2 or VAM-IHCA participants, unless otherwise specified. For data reported as median (IQR), P -values were determined using the Mann Whitney U test. For data reported as percentages, P -values were determined by Fisher's exact test

^a, Defined as ROSC after ≤ 3 vasopressor doses

^b, VSE 1 and 2 data originate from the pooled subgroup of survivors for ≥ 4 h with postresuscitation shock and available SAP data (intervention, $n = 94$; control, $n = 72$)

^c, Analyses of VAM-IHCA hemodynamic data revealed very similar, early postresuscitation arterial pressures and vasopressor support [2]; consequently, there was likely no significant, between-group difference in the frequency of postresuscitation hypotension

^d, VSE 1 and 2 data originate from the pooled subgroup of survivors for ≥ 24 h (intervention, $n = 94$; control, $n = 69$)

^e, VAM-IHCA data originate from survivors for ≥ 24 h (intervention, $n = 63$; control, $n = 61$)

^f, There was no postresuscitation use of ECMO in the VSE 1 and 2 studies

Table 2 has been updated in this correction and the original article [1] has been corrected.

Published online: 15 August 2024

Reference

1. Mentzelopoulos SD, Chalkias A. A critical reappraisal of vasopressin and steroids in in-hospital cardiac arrest. *Crit Care*. 2024;28:191. <https://doi.org/10.1186/s13054-024-04962-8>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.